

SAFE & QUALITY USE OF MEDICINES GROUP

Meeting

Thursday 6th December 2007 Time: 9.30am to 3.30pm

Attendees

Beth Loe (National Coordinator)	Gillian Bohm (MOH)
Avril Lee (WDHB)	Peter Moodie (PHARMAC)
Gigi Lim (Auck Univ)	Marilyn Crawley (WDHB)
Elizabeth Plant (Taranaki)	Adam McCrae (PHARMAC)
Frances McClure (GP)	Mary Seddon (CMDHB)

Invitees

Graham Robinson (Premec), Julian Tommei (Q&R Managers), Nirasha Parsotam (ADHB)

Minutes

Item	Agenda	Notes/comments	Action Required
1.	Apologies	Kevin Hague, Debi Lawry, Dwayne Crombie, Tim Maling, Roy Morris, Peter Black, Nigel Millar	
2.	Minutes of previous meeting	<ul style="list-style-type: none"> Item 12.2 do we know what range of INR they look at Not sure of actual INR values used but broad range of INRs allowed 	
3.	Matters arising	<p>i. <u>Group membership</u></p> <ul style="list-style-type: none"> Roy Morris has agreed to join the group The expenses for the consumer, Debi's travel expenses & my costs are to be claimed from DHB NZ and hopefully this will be settled prior to the next meeting Discussion around BPAC having a representative on the group <p>ii. <u>Inequitable funding issues</u></p> <ul style="list-style-type: none"> Mary had written to Stephen McKernon, his reply indicated that the responsibility for the funding issue now lay with individual DHBs Beth's letter to Stephen McKernon had been misdirected and had been re-sent, awaiting reply Mary had also written to Stephen McKernon about labelling and packaging issues, his reply indicated that Medsafe were planning to arrange a meeting for all parties involved with labelling & packaging issues 	<p>i. <u>Group Membership</u></p> <ul style="list-style-type: none"> Agreed to write to BPAC asking for them to nominate someone and the group will consider the nomination (Beth) <p>ii. <u>Inequitable funding issues</u></p> <ul style="list-style-type: none"> Ask for examples from secondary care through CMO and from primary care through GP liaisons and PHO's (Beth)
4.	PreMec funding	<ul style="list-style-type: none"> Graham Robinson presented the PreMec view & stressed that communication was the major issue with particular reference to DHB communication with GPs and PHOs How can GPs and hospitals improve communication through Healthlink? Discussion on the best method for delivering SQM messages to individual GPs in a user friendly, meaningful way & also methods that could be employed to influence prescribers' practice SQM recognise that they need greater primary care representation 	<ul style="list-style-type: none"> Investigate possibility of presenting at GP conferences (Gillian) Prepare one page of issues to take to PreMec Board (Elizabeth, Beth)

		<ul style="list-style-type: none"> • Possibly focus on medicines reconciliation as a linking project between all sectors • Options to improve communication:- <ul style="list-style-type: none"> ◦ A written communication strategy could be helpful, suggestions included either through national facilitators group or clinical governance committees in PHOs ◦ Present at GP conference to broadcast that we exist and investigate other GP forums (IPAC, NZMA, Goodfellow annual CME courses etc) ◦ Format of alerts changed so that action points on front, background information on the back 	
5.	QIC update	<ul style="list-style-type: none"> • Business cases for all projects have been signed off by Minister, DHBNZ to assign a CE to lead individual projects • A steering group is needed to scope the process • HISO and HISAC are working on terminology and e prescribing but there is no link to the data synchronisation process (i.e. gtns). This should be recognised as an important element • SQM should signal to HISAC, QIC and DG Health that there is significant clinical risk occurring because of this • Reference groups needed and should include doctors, nurses and pharmacists; national drug chart already has a multidisciplinary sub-committee, medicines reconciliation suggested Gillian, Mary, Elizabeth, Beth 	<ul style="list-style-type: none"> • Alert HISAC, QIC & DG Health (Elizabeth)
6.	DHB medication safety groups	<ul style="list-style-type: none"> • Defer to next meeting 	<ul style="list-style-type: none"> • Agenda next meeting (Beth)
7.	Linking ADR/allergy to NHI	<ul style="list-style-type: none"> • There is currently nothing that can be done about this • HISAC & Medicines Management project need to be informed of the issue • PHOs are able to download updated information every 3 months 	<ul style="list-style-type: none"> • Inform HISAC (Elizabeth) • Review when medicines management project starts
8.	E prescribing briefing paper	<ul style="list-style-type: none"> • This was raised at HISAC • HISAC currently concentrating on GP to community pharmacist link • Still awaiting final version of paper before presenting to QIC 	<ul style="list-style-type: none"> • Finalise paper (Gillian, Nigel) • Put on QIC agenda (Gillian)
9.	Look alike sound alike names and packaging	<ul style="list-style-type: none"> • Stephen McKernon had indicated to Mary that a meeting between all parties connected to this issue was planned 	
9. i	Lighting/eye sight	<ul style="list-style-type: none"> • Literature search underway, defer to next meeting 	<ul style="list-style-type: none"> • Eyesight/lighting (Nigel)
9.ii	Resus trolley syringes	<ul style="list-style-type: none"> • Issue should be raised with HPAC initially so they can request products be sent out for tender by PHARMAC 	<ul style="list-style-type: none"> • Write to HPAC (Marilyn)
9.iii	INN v BAN	<ul style="list-style-type: none"> • A large number of medicines are now coming in labelled with the rINN and not all are readily identifiable to the BAN name e.g. methyltrimeprazine (BAN) v levomepromazine (rINN) • NPSA & MHRA in UK have issued warnings and a patient information leaflet (PIL) about this • Discussed options on how health professionals and patients awareness of this issue can be raised 	<ul style="list-style-type: none"> • Check if BPAC journal included article on this & submit one (Beth) • Write to Medsafe about our concerns and suggest an awareness campaign/ patient information leaflet (Beth) • Investigate if this can be

		<ul style="list-style-type: none"> Do the Medsafe TOR include safety issues for medicines once registered Include in Notes on Injectable Drugs where appropriate Providing information to individual patients will be a huge job for pharmacists, a PIL would help but will need funding Possibility of highlighting issue through HDC discussed 	<p>highlighted in Pharmaceutical Schedule (Adam)</p> <ul style="list-style-type: none"> Add to nursing textbook if possible that includes section on lookalike, sound alike names (Gigi) Investigate re-write of UK PILS and how it can be published & distributed (Beth & Adam) Raise issue with MARC (Beth)
10.	National Drug Chart	<ul style="list-style-type: none"> Multiple feedback about practical details but overall people supportive Sub committee met and have agreed some changes in response to consultation, re-working of chart in progress Feedback from MOH was all positive MOH would like a similar chart design for use in aged care facilities Consider promoting new look chart when medicine strategy officially launched (possibly 14.12.07) Need a project manager to organise a pilot and produce associated resources because of the change management required, possibly seconded to the MOH 	<ul style="list-style-type: none"> Continue to work on changes to chart (Beth) Investigate way forward for a trial (Beth, Gillian, Kevin)
11.	Alerts of Toniq dispensing system	<ul style="list-style-type: none"> Warnings for methotrexate, warfarin and colchicine drafted Pharmacy Council are developing warnings for tramadol, lithium and clozapine Warnings need to be shorter and fewer 	<ul style="list-style-type: none"> Review warnings and send changes to Beth (All)
12.	Pharmac funding of SQM project	<ul style="list-style-type: none"> It was agreed that the project for 07/08 would be development of a QUM map Map either linked with Australian system so NZ is an attached island or a NZ map with SQM as reference group and national coordinator to update once the "map" was set up 	<ul style="list-style-type: none"> Move forward (Adam)
13.	BPAC articles	<ul style="list-style-type: none"> Article on INN v BAN names prepared 	<ul style="list-style-type: none"> Talk to BPAC (Beth)
14.	High Risk Medicines		
14.i	Potassium & heparin pre mixes	<ul style="list-style-type: none"> Baxters have raised the labelling of the heparin premixes with their Australian production team 	<ul style="list-style-type: none"> Investigate if heparin syringes could be available commercially (Beth)
14.ii	Warfarin	<ul style="list-style-type: none"> Possibility that Glaxo are going to produce the flipchart developed by Anne Blumgart at Middlemore Suggest include audit methods Reconvene working group of Beth, Avril and Anne Consider applying for research funding to investigate the impact of the toolkit eg PERF funding 	<ul style="list-style-type: none"> Update quotes for toolkit (Beth, Avril) Re-visit what is in toolkit (Working group) Include toolkit and costings in letter to PreMec (Beth)
14.iii	LMWH	<ul style="list-style-type: none"> PHARMAC currently unable to format alerts due to workload Formatted by Beth, comments on format and the changed wording to Beth Change so important information on the front and background etc on the reverse 	<ul style="list-style-type: none"> Update, circulate electronically for final sign off and distribute (Beth)
14.iv	Morphine	<ul style="list-style-type: none"> Awaiting formatted version 	<ul style="list-style-type: none"> Send alert out for consultation (Beth)

14.v	Intravenous Infusions	<ul style="list-style-type: none"> Audit package given to the Q & R managers at their November meeting with a closing date of Feb 28th because of the summer holidays 	<ul style="list-style-type: none"> Send out reminder about audit end of Jan (Beth)
14.vi	Good Prescribing Practice	<ul style="list-style-type: none"> Contacted Mims and they are looking into Mims compliance with the alert 	<ul style="list-style-type: none"> Follow up with Mims (Beth)
14.vii	IT cytotoxic injection	<ul style="list-style-type: none"> There have been no reports of an incident in NZ Medsafe have initiated a project around this and written to manufacturers requiring them to only supply vincristine in minibags and with recommended labelling instructions This is a positive move by Medsafe The additional costs have been passed on to purchasers who were not aware that Medsafe had made this recommendation 	<ul style="list-style-type: none"> Guidelines on website when site goes live (Beth) Investigate taking guidelines and presenting to haematologists (Beth) Send alert to Baxters (Beth) Invite Medsafe to February meeting
14.viii	Colchicine	<ul style="list-style-type: none"> Changes made to alert following consultation Re-format in line with PreMec suggestion, actions on front, background on the reverse Pharmac preparing a patient information pamphlet "Out with gout – how to live a healthy life with gout" 	<ul style="list-style-type: none"> Re-format and send round for sign off by group (Beth)
14.ix	Oral Methotrexate	<ul style="list-style-type: none"> No progress 	<ul style="list-style-type: none"> Contact John O'Donnell (Beth)
15.	Renal drug dosing	<ul style="list-style-type: none"> To be re-formatted 	<ul style="list-style-type: none"> Re-format alert (Tim)
16.	Annual report	<ul style="list-style-type: none"> Forward, suggested would be appropriate if Minister wrote this Discussion on the various sections and who should write them (list sent separately) Pieces to be submitted to Gillian by January 24th 2008 	<ul style="list-style-type: none"> Individual sections (All) Send out reminder (Beth)
	Primary Care	<ul style="list-style-type: none"> This needs to be an agenda item at each meeting 	<ul style="list-style-type: none"> Add to agenda (Beth)
	IHI program availability	<ul style="list-style-type: none"> Baxters because of their sponsorship of IHI in the US have the IHI program available It was initially planned as a video link but because of the time difference this was considered impractical They are able to offer the program on DVDs and wonder if the group see a use for these and how they could be offered to a wide audience The program other than the annual forum is not particularly relevant and the keynote speeches from the forum will be available on the IHI website 	<ul style="list-style-type: none"> Respond to Baxters (Beth)
	Formulary	<ul style="list-style-type: none"> Elizabeth's paper was discussed very briefly at SIG and SIG decided not to proceed with a formulary PHARMAC will develop a business case to take to SIG 	<ul style="list-style-type: none">
	International Network of Safe Medication Practice Centres	<ul style="list-style-type: none"> Tim has submitted a report for 2006-7 on our behalf 	<ul style="list-style-type: none">
17.	Dates and venues for 2008 meetings	<ul style="list-style-type: none"> Discussion about day because Kevin is unable to attend on Thursdays Changing the day would mean other people would be affected 	<ul style="list-style-type: none"> February 14th Wellington April 10th Auckland June 12th Wellington August 7th Auckland

		<ul style="list-style-type: none">• It was decided to stay with Thurs in the interim and review at the February meeting	<ul style="list-style-type: none">• October 23rd Wellington• December 11th Auckland
--	--	---	--